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Abstract
Advances in clinical lipidology during the last 18 months include the establishment of high-sensitivity
C-reactive protein (hsCRP) as an important risk marker for cardiovascular disease. Determining
hsCRP levels should help the clinician single out patients at particularly high risk. However, more
research needs to be done in this area. Furthermore, statins do not seem to be of benefit in patients
with severe congestive heart failure, on chronic hemodialysis, or with aortic stenosis. Next, plasma
triglyceride levels are now considered an important risk marker for cardiovascular disease, but the
therapeutic benefits related to lowering triglyceride levels remain difficult to achieve. Also, nicotinic
acid has gained more interest partly because recent studies have demonstrated positive effects on
atherosclerosis development and partly because the side effect of flushing seems to be partially
avoidable with the concomitant administration of laropiprant. Both the raising of high-density
lipoprotein cholesterol by nicotinic acid and the additional lowering of low-density lipoprotein
cholesterol by ezetimibe and eprotirome will need to demonstrate hard endpoint reductions in large-
scale intervention trials. Trials of niacin/laropiprant (the AIM-HIGH and HPS2-THRIVE studies) and
ezetimibe (the IMPROVE-IT study) are already under way.
Introduction and context
In recent years, considerable achievements have been
realized in the prevention of fighting cardiovascular
disease by modifying blood lipid levels. C-reactive
protein has proven to be an important additional risk
indicator amenable to therapy with statins. The
limitation of statin therapy has also been defined in
several studies in patients with diseases that share
some characteristics with atherosclerosis (e.g., aortic
valve and kidney disease). Several drugs have been
used in efforts to further diminish low-density lipo-
protein cholesterol (LDL-C) and thereby further
decrease cardiovascular risk. Triglyceride lowering in
patients with diabetes has shown disappointing results.
Increases in putatively cardioprotective high-density




As high-sensitivity C-reactive protein (hsCRP) has been
shown to predict cardiovascular disease [1], it has been of
interest to study to what extent people with elevated
hsCRPcouldbenefitfromlipidlowering.Thiswasdonein
the JUPITER (Justification for the Use of Statins in
Prevention:AnInterventionTrialEvaluatingRosuvastatin)
study [2]; 17,802 healthy men and women with LDL-C of
below130mg/dL(3.4mmol/L)andhsCRPof2.0mg/Lor
higher were randomly assigned to rosuvastatin 20 mg or
placebo. The hazard ratio (HR) of the primary endpoint
was 0.56 (P < 0.00001). In a subsequent subgroup
analysis [3], it was demonstrated that in participants
who achieved LDL-C of below 70 mg/dL (1.8 mmol/L)
and hsCRP of less than 1 mg/L, significant (79%)
reduction occurred. The achieved hsCRP concentrations
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endpoint, including the apolipoprotein B to A-1 ratio.
Clinical limitations of statin treatment
Statin treatment for coronary heart disease has been very
successful, as demonstrated in many large-scale inter-
ventional studies. Subgroup analyses of these studies
have often indicated beneficial outcomes in diagnoses
related to the primary therapeutic goal. Therefore, statin
treatment has been tried in a number of diseases that are
clinically close to atherosclerosis. In general, such studies
have produced negative or neutral outcomes and
disappointments. This was the case with a randomized
control study of rosuvastatin in congestive heart failure
in the CORONA (Controlled Rosuvastatin Multinational
Trial in Heart Failure) study [4], although a limited
effect was seen in the GISSI (Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Miocardico) study [5] using
omega-3 fatty acid as the active treatment. Further
analysis of the CORONA study showed that patients in
the lowest tertile of plasma amino-terminal pro-brain
natriuretic peptide (NT-proBNP), a marker of cardiac
dysfunction, had the best prognosis and, if assigned to
rosuvastatin instead of placebo, had a greater reduction
in the primary endpoint than patients in the other tertiles
(heterogeneity test, P = 0.0192) [6]. This reflected fewer
atherothrombotic events and sudden deaths with rosu-
vastatin. It was concluded that patients with heart failure
due to ischemic heart disease who have NT-proBNP
values of less than 103 pmol/L (868 pg/mL) may benefit
from rosuvastatin. Also, in a retrospective hypothesis-
generating study, the CORONA authors found a sig-
nificant interaction between hsCRP and the effect of
rosuvastatin for most endpoints, and rosuvastatin treat-
ment was associated with better outcomes in patients
with hsCRP of at least 2.0 mg/L [7].
In the AURORA (A Study to Evaluate the Use of
Rosuvastatin in Subjects on Regular Hemodialysis: An
Assessment of Survival and Cardiovascular Events)
study, rosuvastatin was tried in patients treated with
hemodialysis because of renal failure and the outcome
was neutral [8]. The AURORA study thereby confirmed
what was previously seen in the 4D (Die Deutsche
Diabetes Dialyse) study using atorvastatin [9]. In the
SEAS (Simvastatin and Ezetimibe in Aortic Stenosis)
study, statin plus ezetimibe was shown not to benefit
patients with aortic stenosis [10]. However, ischemic
events were positively affected by this combined LDL-C-
lowering treatment.
Triglyceride lowering: the ACCORD study
In a subgroup analysis of the IDEAL (Incremental
Decrease in End Points Through Aggressive Lipid
Lowering) and TNT (Treating to New Target) studies,
the role of triglycerides as a cardiovascular disease
predictor during statin treatment was evaluated [11].
After age, gender, and study were adjusted for, risk of
cardiovascular events increased with increasing triglycer-
ide levels. Patients in the highest quintile had a rate of
events that was 63% higher than that of patients in the
lowest quintile (HR 1.63, 95% confidence interval 1.46-
1.81), and the relation of triglycerides to risk was
apparent even within the normal range of triglycerides.
However, when HDL-C, the ratio of apolipoprotein B to
A-1, diabetes, body mass index, glucose, hypertension,
and smoking were included in the statistical analysis,
triglycerides were abolished as a significant predictor of
cardiovascular events. The authors concluded that even
slightly increased triglyceride levels are associated with
higher risk of recurrence of cardiovascular events in
statin-treated patients and should be considered a useful
marker of risk.
The effect of lowering triglyceride levels on cardiovas-
cular disease risk with a statin plus fenofibrate as
compared with statin monotherapy was evaluated in
patients with type 2 diabetes in the lipid arm of the
ACCORD (Action to Control Cardiovascular Risk in
Diabetes) study [12]. The study included 5518 patients
who were followed up for 4.7 years. While LDL-C did not
differ between study treatments, triglyceride levels were
significantly lower and HDL-C was significantly higher in
the fenofibrate-treated group. The HR of the primary
cardiovascular outcome in the fenofibrate group was
0.92 (P = 0.32). Secondary outcomes did not differ
either. Subgroup analysis indicated a gender difference
with higher risk of cardiovascular events in women in the
fenofibrate arm. Those who had high triglyceride and
low HDL-C levels also seemed to do better than the
others (P = 0.06) but this was barely significant.
ARBITER 6-HALTS
The ARBITER 6-HALTS (Arterial Biology for the Investi-
gation of the Treatment Effects of Reducing Cholesterol
6 – High-Density Lipoprotein and Low-Density Lipo-
protein Treatment Strategies) study evaluated the differ-
ence in the development of carotid intima-media
thickness (CIMT) between patients treated with niacin
or ezetimibe. All patients had coronary artery disease or
were at high risk for such an event. They were on statin
treatment and were randomly assigned to niacin or
ezetimibe. The mean HDL-C increased by 18% in the
niacin-treated group, and LDL-C and triglycerides were
also significantly decreased. Ezetimibe lowered LDL-C by
19%. Niacin significantly decreased CIMT, whereas
CIMT was essentially unchanged in the ezetimibe
group (P = 0.003 between groups). The incidence of
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the niacin group than in the ezetimibe group. Will an
additional decrease in LDL-C by combining ezetimibe
with statin treatment add clinical benefit and be safe?
The final answer to this question will have to await
the publication of the IMPROVE-IT (Improved Reduc-
tion of Outcomes: Vytorin Efficacy International Trial)
study [13].
Tredaptive
Niacin therapy has been available for decades but its use
has been hampered because it can cause frequent
flushing of the skin. The mechanism of flushing was
recently elucidated, and a prostaglandin receptor blocker
laropiprant was demonstrated to significantly improve
this side effect [14]. Merck (Darmstadt, Germany) has
developed an extended-release niacin tablet together
with laropiprant and this drug combination, named
Tredaptive, has proven to be efficient in improving
blood lipid levels with considerably diminished flushing
[15]. Tredaptive has been approved for sale in the
European Union but not in the US. This therapy is now
being tested for clinical efficacy and safety in a large-scale
intervention study: HPS2-THRIVE (Heart Protection
Study 2 Treatment of High-Density Lipoprotein to
Reduce the Incidence of Vascular Events).
Eprotirome
The fact that atherosclerotic cardiovascular disease is
only partially reversed by statin treatment has also
prompted scientists to try to decrease LDL-C to levels
that are lower than those obtained by even the most
powerful statin. Ezetimibe is one example of such an
effort. Another such candidate is eprotirome. Eprotir-
ome is a thyromimetic compound that has minimal
uptake in nonhepatic tissues and has affinity for the
triiodothyronine receptor b isoform, which mediates
the lipid-lowering actions of thyroid hormone. This
cholesterol-lowering compound is free of other thyr-
omimetic effects. In a recent paper, it was demonstrated
that 25, 50, or 100 mg daily added to statin treatment for
12 weeks in patients with hypercholesterolemia further
decreased LDL-C by 22%, 28%, and 32%, respectively.
This promising drug will need further safety and efficacy
evaluations in studies with clinical endpoints as the
outcome measure.
Implications for clinical practice
Recent publications within the lipid field have both
expanded and limited the use of drugs affecting lipid
metabolism. The JUPITER study revealed that hsCRP
may be a valuable risk assessment tool and may help
delineate subjects who would particularly benefit from
statin treatment. It has to be kept in mind, however, that
many participants in the JUPITER study already had a
substantial risk, including hypertension and metabolic
syndrome.
Statin treatment of patients with congestive heart failure
or on chronic hemodialysis does not improve their
cardiovascular risk. Furthermore, even if ischemic events
did decrease in statin-treated patients with aortic
stenosis, the treatment did not retard the development
of the valve disease. Another limitation was revealed
with fibrate treatment in type 2 diabetes; the ACCORD
lipid study demonstrated a conclusion similar to that of
the FIELD (Fenofibrate Intervention and Event Lowering
in Diabetes) study: fenofibrate does not improve out-
come when indiscriminately prescribed to patients with
type 2 diabetes. On the other hand, diabetes patients
with high triglyceride and low HDL levels seem to have a
limited benefit from fibrate treatment.
The results of the ARBITER 6-HALTS study and the
upcoming availability of Tredaptive as a niacin that
causes less flushing are promising with regard to niacin
as a drug to add to ongoing statin treatment. These
results point to the rapidly increasing interest in elevating
HDL-C to further decrease cardiovascular risk. Alterna-
tively, two drugs may help further decrease atherogenic
LDL-C: ezetimibe and eprotirome. Large endpoint
studies are needed to establish these new therapies in
the lipid field of cardiovascular prevention. A study of
ezetimibe, the IMPROVE-IT study, is already under way.
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